Patents by Inventor Ihsan Hamdi Nijem

Ihsan Hamdi Nijem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pertuzumab plus trastuzumab fixed dose combination
    Patent number: 12252549
    Abstract: The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: March 18, 2025
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Tanja Badovinac-Crnjevic, Yu Chien Fredriksson, Sarah Heeson, Ihsan Hamdi Nijem, Whitney Paige Kirschbrown, Eleonora Restuccia
  • PERTUZUMAB PLUS TRASTUZUMAB FIXED DOSE COMBINATION
    Publication number: 20210403599
    Abstract: The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.
    Type: Application
    Filed: June 28, 2021
    Publication date: December 30, 2021
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Tanja Badovinac-Crnjevic, Yu Chien Fredriksson, Sarah Heeson, Ihsan Hamdi Nijem, Whitney Paige Kirschbrown, Eleonora Restuccia